A detailed history of Citigroup Inc transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Citigroup Inc holds 65,735 shares of EDIT stock, worth $160,393. This represents 0.0% of its overall portfolio holdings.

Number of Shares
65,735
Previous 65,853 0.18%
Holding current value
$160,393
Previous $307,000 27.04%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$3.39 - $5.96 $400 - $703
-118 Reduced 0.18%
65,735 $224,000
Q2 2024

Aug 12, 2024

SELL
$4.67 - $7.28 $2.92 Million - $4.56 Million
-626,080 Reduced 90.48%
65,853 $307,000
Q1 2024

May 10, 2024

BUY
$7.03 - $11.07 $3.81 Million - $6 Million
541,839 Added 361.0%
691,933 $5.13 Million
Q4 2023

Feb 09, 2024

SELL
$6.25 - $11.11 $390,550 - $694,241
-62,488 Reduced 29.39%
150,094 $1.52 Million
Q3 2023

Nov 09, 2023

BUY
$6.92 - $9.31 $176,681 - $237,702
25,532 Added 13.65%
212,582 $1.66 Million
Q2 2023

Aug 10, 2023

SELL
$6.36 - $11.47 $2.83 Million - $5.11 Million
-445,421 Reduced 70.43%
187,050 $1.54 Million
Q1 2023

May 11, 2023

BUY
$7.03 - $11.53 $2.01 Million - $3.3 Million
286,589 Added 82.86%
632,471 $4.59 Million
Q4 2022

Feb 09, 2023

SELL
$8.32 - $13.21 $680,709 - $1.08 Million
-81,816 Reduced 19.13%
345,882 $3.07 Million
Q3 2022

Nov 10, 2022

SELL
$12.16 - $19.42 $736,519 - $1.18 Million
-60,569 Reduced 12.4%
427,698 $5.24 Million
Q2 2022

Aug 10, 2022

BUY
$9.99 - $21.35 $4.05 Million - $8.65 Million
405,097 Added 487.07%
488,267 $5.78 Million
Q1 2022

May 12, 2022

SELL
$14.08 - $27.63 $1.41 Million - $2.77 Million
-100,275 Reduced 54.66%
83,170 $1.58 Million
Q4 2021

Feb 10, 2022

BUY
$26.55 - $40.57 $3.01 Million - $4.6 Million
113,444 Added 162.06%
183,445 $4.87 Million
Q3 2021

Nov 10, 2021

BUY
$39.27 - $72.94 $2.75 Million - $5.11 Million
70,001 New
70,001 $2.88 Million

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $168M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.